Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox (Mpox) Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Apoptosis induction by TRAIL
- TRAIL: a member of the TNF superfamily
- TNF-related apoptosis-inducing ligand (TRAIL)
- TRAIL-R belong to the TNF-R superfamily
- The death receptors
- The TRAIL system
- TRAIL DISC formation
- c-FLIPS/c-FLIPL inhibit TRAIL-mediated apoptosis
- Caspase 10
- Caspase-10 is recruited to CD95 and TRAIL
- Caspase-10 cannot substitute caspase-8
- Caspase-10 protein expression is lost in tumors
- Isoforms of caspase-10 and caspase-8
- No differential cleavage for RIP and TRAF-1
- Caspase-3 is cleaved by caspase-8 and -10
- Caspase-8 and -10 generates different proteins
- Summary and conclusion (caspase-8 versus -10)
- Death receptors
- The TRAIL system: can we kill tumor cells?
- LZ-TRAIL induces apoptosis in tumor cell lines
- Effect of TRAIL on normal human cells in vitro
- TRAIL treatment of a subcutaneous tumor
- Efficacy of TRAIL treatment in tumors
- Inhibition of etoposide-induced apoptosis by Bcl-x
- Double hit on tumor cells
- Safety of TRAIL treatment: alone and in synergy
- TRAIL versus CD95L in vivo
- Sensitivity of PHH to TRAIL and to CD95L
- Sensitivity and resistancy of PHH to TRAIL
- HepG2 sensitivity to various forms of TRAIL
- PHH are sensitive to one form of TRAIL only
- Sensitisation of PHH by chemotherapeutics
- Summary and conclusion (TRAIL on PHH)
- What determines TRAIL sensitivity vs. resistance?
- Sensitivity of various Hep cells to TRAIL
- Proteasome inhibitors sensitise HC for TRAIL
- Proteasome inhibition: TRAIL-induced apopotosis
- Proteasome inhibition results in NF-kB inhibition
- Proteasome inhibitors: upregulation of TRAIL-R1,2
- TRAIL upregulation unnecessary for sensitisation
- Proteasome inhibition enhances TRAIL formation
- TRAIL sensitisation at the DISC level
- Crosstalk between the two death pathways
- Division of apoptosis regulation (DO40)
- Thank you
Topics Covered
- poptosis induction by the TNF-related apoptosis-inducing ligand (TRAIL)
- Apoptosis-inducing TNF super-family ligands and receptors
- Formation of the deathinducing signalling complex (DISC)
- Caspase-8 versus caspase-10
- Synergy of TRAIL with chemotherapeutics
- Tumour specificity of TRAIL-induced apoptosis
- Regulation of sensitivity versus resistance towards TRAIL-induced apoptosis
Talk Citation
Walczak, H. (2007, October 1). TRAIL-induced apoptosis: from analysis of the death-inducing signalling complex (DISC) to clinical applicability [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 21, 2024, from https://doi.org/10.69645/SRJE9848.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Henning Walczak has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
TRAIL-induced apoptosis: from analysis of the death-inducing signalling complex (DISC) to clinical applicability
Published on October 1, 2007
27 min
A selection of talks on Cell Biology
Hide